Kimberly-Clark’s $40 billion bid for Tylenol maker Kenvue won approval from the European Union after Kimberly-Clark offered to divest its tampon and feminine hygiene brands in the European Economic Area. The European Commission—the EU’s executive arm—said Tuesday that the sale fully addresses officials’ earlier concerns that the deal could hinder competition in tampon markets in Czech Republic, Estonia, and Slovakia. The EU’s nod clears a regulatory hurdle for the deal, which will give birth to a global health conglomerate by combining the makers of Huggies diapers and Johnson’s baby care products. Kimberly-Clark announced its bid for Kenvue in November 2025. [to access the full story a WSJ subscription is required]